Dynavax Technologies Co. (NASDAQ:DVAX) Receives Average Rating of “Buy” from Analysts

Share on StockTwits

Dynavax Technologies Co. (NASDAQ:DVAX) has earned an average rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $12.50.

Several brokerages have recently commented on DVAX. Zacks Investment Research upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a report on Friday, August 16th. BidaskClub upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Thursday. ValuEngine upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. William Blair restated a “buy” rating on shares of Dynavax Technologies in a report on Friday, August 16th. Finally, Royal Bank of Canada reduced their target price on shares of Dynavax Technologies to $13.00 and set an “outperform” rating on the stock in a report on Friday, May 24th.

In other Dynavax Technologies news, Director Francis Cano bought 16,667 shares of Dynavax Technologies stock in a transaction on Monday, August 12th. The shares were bought at an average cost of $3.00 per share, for a total transaction of $50,001.00. Following the acquisition, the director now directly owns 118,484 shares in the company, valued at $355,452. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Robert Coffman sold 32,218 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $4.58, for a total transaction of $147,558.44. Following the sale, the senior vice president now owns 132,470 shares in the company, valued at $606,712.60. The disclosure for this sale can be found here. 4.90% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the business. Marshall Wace North America L.P. acquired a new stake in Dynavax Technologies during the 1st quarter worth approximately $1,468,000. Chicago Capital LLC raised its holdings in shares of Dynavax Technologies by 18.8% in the 1st quarter. Chicago Capital LLC now owns 2,544,142 shares of the biopharmaceutical company’s stock valued at $18,598,000 after purchasing an additional 402,411 shares in the last quarter. Clearbridge Investments LLC raised its holdings in shares of Dynavax Technologies by 3.4% in the 1st quarter. Clearbridge Investments LLC now owns 1,161,338 shares of the biopharmaceutical company’s stock valued at $8,489,000 after purchasing an additional 38,400 shares in the last quarter. BNP Paribas Arbitrage SA raised its holdings in shares of Dynavax Technologies by 56,326.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 12,978 shares of the biopharmaceutical company’s stock valued at $95,000 after purchasing an additional 12,955 shares in the last quarter. Finally, Bailard Inc. raised its holdings in shares of Dynavax Technologies by 52.8% in the 1st quarter. Bailard Inc. now owns 149,000 shares of the biopharmaceutical company’s stock valued at $1,089,000 after purchasing an additional 51,500 shares in the last quarter. Institutional investors own 82.41% of the company’s stock.

Dynavax Technologies stock opened at $4.32 on Tuesday. The firm has a 50 day simple moving average of $3.51 and a 200-day simple moving average of $6.13. Dynavax Technologies has a 1-year low of $2.60 and a 1-year high of $14.35. The company has a debt-to-equity ratio of 19.95, a current ratio of 4.30 and a quick ratio of 3.47.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.03). Dynavax Technologies had a negative net margin of 781.10% and a negative return on equity of 304.71%. The firm had revenue of $8.30 million during the quarter, compared to analysts’ expectations of $8.24 million. During the same period last year, the company earned ($0.63) EPS. The business’s quarterly revenue was up 564.0% on a year-over-year basis. Equities analysts forecast that Dynavax Technologies will post -1.99 EPS for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Featured Story: How is a buy-side analyst different from a sell-side analyst?

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Analysts Expect Santander Consumer USA Holdings Inc  to Post $0.67 Earnings Per Share
Zacks: Analysts Expect Santander Consumer USA Holdings Inc to Post $0.67 Earnings Per Share
Dynavax Technologies Co.  Receives Average Rating of “Buy” from Analysts
Dynavax Technologies Co. Receives Average Rating of “Buy” from Analysts
Cara Therapeutics Inc  Expected to Announce Earnings of -$0.59 Per Share
Cara Therapeutics Inc Expected to Announce Earnings of -$0.59 Per Share
Essential Properties Realty Trust Inc  Receives Consensus Recommendation of “Hold” from Analysts
Essential Properties Realty Trust Inc Receives Consensus Recommendation of “Hold” from Analysts
CGI Inc  Expected to Post Quarterly Sales of $2.27 Billion
CGI Inc Expected to Post Quarterly Sales of $2.27 Billion
BankFinancial Co.  Expected to Post Earnings of $0.22 Per Share
BankFinancial Co. Expected to Post Earnings of $0.22 Per Share


© 2006-2019 Ticker Report